Press Archive

Here, we provide a list of earlier press releases. Please visit our blog for the latest company news and press releases.

04.2020
SARomics Biostructures, Red Glead Discovery, and researchers at Sahlgrenska Cancer Center jointly collaborated on this project, which was one of 15 financed by Swelife to enhance health and well-being and increase the sustainable growth and competitiveness of the Swedish life science sector. In the project, a preclinical innovative epigenetic therapy will be significantly advanced toward clinical studies for an orphan cancer indication. Read more…

02.2020
Aqilion AB contracts an integrated drug discovery project with SARomics Biostructures and Red Glead Discovery. The project aims to develop drug candidates that bind to a target protein essential in the development of malignant disease and inflammatory conditions. A successful project can, therefore, help develop new medications to treat orphan drug indications in the field of autoinflammatory diseases, as well as new combination therapies within the field of oncology, particularly in the treatment of intestinal cancer. Read more…

07.2019
SARomics Biostructures and Red Glead Discovery acquired the weak-affinity chromatography (WAC™) technology from Transientic Interactions AB.

10.2018
SARomics Biostructures will use its 3D structure determination capabilities to assist Alligator Bioscience AB, a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, to verify the unique functionality of ATOR-1017, an immuno-stimulatory antibody in development for the treatment of metastatic cancer. Read more…

10.2017
The University of Copenhagen, SARomics Biostructures, and Enamine have joined forces to develop the next generation of safer antidepressants in an EU-funded project, Selective Agonists For Serotonin Receptors (SAFER). Read more…

08.2016
SARomics Biostructures & Carna Biosciences sign an exclusive distribution agreement covering the Japanese market. Press release…

05.2015
SARomics Biostructures and Merozyne Therapeutics AB have announced a collaboration on a project to develop a pharmaceutical treatment for laminin alpha2 chain-deficient congenital muscular dystrophy (MDC1A). Read more…

01.2014
SARomics Biostructures and Xbrane Bioscience form a strategic partnership for “off-the-shelf” protein structures. Press release…

02.2014
SARomics Biostructures and BioVersys join efforts to combat multidrug-resistant bacterial infections. Press release…

03.2014
SARomics Biostructures is the first Nordic company to obtain growth capital through a collaborative initiative between Sparbanken Öresund and the European Investment Fund. Press release…

09.2014
Poster presentation within the TAKTIC project
Towards a Bioisosteric Alkaest: application to the bioisosteric modulation of IMD-0354. Download poster..

04.2013
SARomics Biostructures coordinates the TAKTIK project, an EU-funded industry-academia partnership focused on drug discovery for protein kinases. Press release…

10.2012
SARomics Biostructures and Red Glead Discovery enter lead discovery collaboration focusing on epigenetic disorders. Press release…

09.2012
SARomics Biostructures brings in new strategic owners. Press release…

02.2011
SARomics Biostructures coordinates the KINOMED, Eurostars-funded kinase project. Press release…

12.2010
Inimex Pharmaceuticals and SARomics Biostructures announce the achievement of a key scientific milestone in Structural Biology Collaboration. Press release…
See also our blog article on the story of this project.

12.2010
SARomics Biostructures and Vectron Biosolutions have announced a partnership to offer a joint service to the life sciences industry. This service will cover customized gene-to-structure projects, utilizing Vectron Biosolutions’ expertise in protein production and SARomics Biostructures’ expertise in protein crystallization and structure determination. Read more…

09.2009
UNIZYME Laboratories A/S, Hørsholm, Denmark, and SARomics AB, Lund, Sweden, announced a research service collaboration to discover novel lead compounds targeting dipeptidyl peptidase I (DPPI; cathepsin C) for the treatment of inflammatory diseases. Press release…

11.2008
The Lund-based structural biology contract research company SARomics Biostructures AB announced today that it will expand its range of services to include academic groups. Compared to corporate customers, the academic groups will gain access to protein crystallization and protein structure determination services at prices that should prove highly competitive with the traditional model of academic collaboration. Read more…

09.2007
Alligator Bioscience, the protein optimization company, announced that it has entered into a strategic collaboration agreement with SARomics. Alligator Bioscience intends to offer the services performed at SARomics as an integral part of Alligator Bioscience. It aims to leverage SARomics’ technology and expertise through its technology platform to reduce the time required for internal and external projects. Read more…